%20LIMITED%2030-Jan-2007_files/image002.jpg)
MIRA
INFORM REPORT
|
Report Date : |
30th
January, 2007 |
IDENTIFICATION
DETAILS
|
Name : |
JAWA
PHARMACEUTICALS (PVT) LIMITED |
|
|
|
|
Formerly Known as: |
MIAN BROTHERS LABORATORIES (PVT) LTD |
|
|
|
|
Registered Office : |
112/10 Quaid-e-Azam Industrial Area, Kot Lakhpat, Lahore,
Pakistan |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1987 |
|
|
|
|
Com. Reg. No.: |
L-00037/19870202 |
|
|
|
|
Legal Form : |
Private
Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Business Name
JAWA PHARMACEUTICALS (PVT) LIMITED
Full Address
|
Registered Address & Factory |
|
112/10 Quaid-e-Azam Industrial Area, Kot Lakhpat, Lahore,
Pakistan |
|
Tel |
92
(42) 5142041 - 45 (5 Lines) |
|
Fax |
92
(42) 5110906 |
|
Email |
Short Description Of Business
|
a. |
Nature
of Business |
Manufacture & Marketing of
Pharmaceutical Products |
|
b. |
Year
Established |
1987 |
|
c. |
Registration
# |
L-00037/19870202 |
Branches
Mainly in Karachi & Islamabad
Auditors
Phinehas
& Co.
(Chartered Accountants)
58 - Main Shadman Market, Lahore, Pakistan
Legal Status & Change of Name
Subject Company was established by the name
of “MIAN BROTHERS LABORATORIES (PVT) LTD
” in 1987 then afterwards its name was changed to “JAWA PHARMACEUTICALS (PVT) LIMITED”
Authorised Capital
Rs. 43,000,000/- divided into 430,000 shares of Rs. 100/- each
Issued & Paid up Capital
Rs. 11,980,000/- divided into 119,800 shares of Rs. 100/- each
Details of Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr.
Sajid Ali Jawa Mr.
Saeeda Jawa Mr.
Baqir Jawa Mr.
Raza Jawa |
Pakistani Pakistani Pakistani Pakistani |
885 - Shadman Colony-1, Lahore
885 - Shadman Colony-1, Lahore
885 - Shadman Colony-1, Lahore 885 - Shadman Colony-1, Lahore |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
Names
Mr. Sajid Ali Jawa
Mr. Saeeda Jawa
Mr. Baqir Jawa
Mr. Raza Jawa
Associates
A. Subsidiary
None
B. Associated Companies
- Do -
Products
AMNIC, AMRID, AMTRIL, AMURAL, BISACODYL,
CHLORAMPHENICOL, EPHEDRINE, ISONIAZIDE, M-BROVIT, M.BROCON, M.BROPHYLLINE,
M.BROPLAST, M.BROPLEX, M.BROVIT, M.BROZINE, MEBROSIL, PARACETAMOL, PHENOBARBITONE,
PIPERAZINE
Number of Employees
160 - 175
Actual Capacity & Production
The capacity and
production of the Company’s plant is indeterminable as it is multi-product and involves varying
processes of manufacture.
Annual Sales Volume
Year In
Pak Rupees
2005 160,000,000/- (Estimated)
Trade Suppliers (Foreign)
(1)
CARGILL, FRANCE.
(2)
HENAN JINDAN LACTIC ACID CO LTD, CHINA.
(3)
AARTI INDUSTRIES LIMITED, INDIA.
(4) DEGUSSA, GERMANY.
Distributors
Mainly in all important cities of Pakistan
Bankers and their addresses
(1) Habib Bank
Limited, The Mall Branch, Bank Square, Lahore, Pakistan. (Finance obtained PKR
10,039,730/-)
Financial Position
Sound
Memberships
·
Pakistan
Pharmaceutical Manufacturers Association.(PPMA)
·
Lahore
Chamber of Commerce & Industry.(LCCI)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 60.87 |
|
UK Pound |
1 |
Rs. 119.10 |
|
Euro |
1 |
Rs. 78.50 |
Comments
Subject Company enjoys good
reputation in Pakistan Pharmaceutical Industry. All the directors are reported
as experienced, respectable and having satisfactory means of their own. Their
trade relations are reported as fair. Payments are usually correct and as per
commitments. The Company can be considered for normal business dealings at
usual trade terms and conditions.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|